Form 4: Predictive Oncology Director Granted 64,680 RSUs

Predictive Oncology Inc. Director Charles Lee Nuzum Sr. was granted 64,680 restricted stock units, vesting October 31, 2025.

Summary

• Charles Lee Nuzum Sr., a Director of Predictive Oncology Inc. (POAI), acquired 64,680 shares of common stock.
• The acquisition was in the form of restricted stock units (RSUs) with a transaction price of $0.00 per unit.
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs are scheduled to vest in full on October 31, 2025, contingent upon continued service through that date.
• Following this transaction, Charles Lee Nuzum Sr. beneficially owns a total of 94,587 shares of common stock directly.

Sentiment

Score: 6

Explanation: Slightly positive, as an equity grant to a director generally aligns interests and is a standard compensation practice, indicating continued commitment.

Positives

• The grant of restricted stock units aligns the director's interests with those of shareholders, incentivizing long-term performance and retention.
• The acquisition of equity by a director can signal confidence in the company's future prospects.

Risks

• The vesting of the restricted stock units is subject to the director's continued service through October 31, 2025, meaning the shares are not immediately owned outright.

Future Outlook

The restricted stock units are scheduled to vest in full on October 31, 2025, provided the director continues their service through that date.

Industry Context

This Form 4 filing reports a routine insider equity grant, which is a common practice across industries to compensate and incentivize directors and executives. It does not provide broader industry trend insights.

Related Party Transactions

• The grant of restricted stock units to Charles Lee Nuzum Sr., a Director, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The restricted stock units will vest on October 31, 2025, subject to the director's continued service.

Key Dates

Keywords

Predictive Oncology, POAI, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director, Equity Grant, Beneficial Ownership